Development of small-molecule therapies for autoimmune diseases

References

• Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009; 373:659–672.
   PubMed Web of Science ®Google Scholar
• Cornillie F. Ten years of infliximab (Remicade) in clinical practice: The story from bench to bedside. Eur J Pharmacol. 2009; 623 Suppl. 1: S1–S4.
   PubMedGoogle Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008; 117:244–279.
   PubMed Web of Science ®Google Scholar
• Stoll JG, Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov. 2009; 8:693–694.
   PubMed Web of Science ®Google Scholar
• Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov. 2009; 8:355–356.
   PubMed Web of Science ®Google Scholar
• Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Tocilizumab. Nat Rev Drug Discov. 2009; 8:273–274.
   PubMed Web of Science ®Google Scholar
• Guercan H, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of Rituximab in autoimmune diseases. Int Immunopharmacol. 2009; 9:10–25.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Wiendl H, Leussink VI, Stüve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol. 2008; 255:15–21.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol. 2009; 36:1118–1125.
   PubMed Web of Science ®Google Scholar
• Keller TH, Pichota A, Yin Z. A practical view of ‘drugability’. Curr Opin Chem Biol. 2006; 10:357–361.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002; 1:727–730.
   PubMed Web of Science ®Google Scholar
• Bleicher KH, Nettekoven M, Peters JU, Wyler R. Lead generation: Sowing the seeds for future success. Chimia. 2004; 58:588–600.
   Web of Science ®Google Scholar
• Lafreniere RG, MacDonald MLE, Dube M-P, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio A-M, Davar G, Breakefield XO, Pimstone SN, Green R, Pryse-Phillips W, Goldberg YP, Younghusband HB, Hayden MR, Sherrington R, Rouleau GA, Samuels ME. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the study of Canadian genetic isolates. Am J Hum Genet. 2004; 74:1064–1073.
   PubMed Web of Science ®Google Scholar
• Halapi E, Hakonarson H. Population genomics of drug response. Am. J. Pharmacogenomics. 2004; 4:73–82.
   PubMedGoogle Scholar
• Duarte CD, Barreiro EJ, Fraga CAM. Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini-Rev Med Chem. 2007; 7:1108–1119.
   PubMed Web of Science ®Google Scholar
• Harris CJ. Letting the target determine your compound acquisition strategy. Drug Discov World. 200919–22.
   Google Scholar
• Harris CJ, Stevens AP. Chemogenomics: Structuring the drug discovery process to gene families. Drug Discov Today. 2006; 11:880–888.
   PubMed Web of Science ®Google Scholar
• Birault V, Harris CJ, Le J, Lipkin M, Nerella R, Stevens A. Bringing kinases into focus: Efficient drug design through the use of chemogenomic toolkits. Curr Med Chem. 2006; 13:1735–1748.
   PubMed Web of Science ®Google Scholar
• Lipkin MJ, Stevens AP, Livingstone DJ, Harris CJ. How large does a compound screening collection need to be?. Comb Chem High Throughput Screen. 2008; 11:482–493.
   PubMed Web of Science ®Google Scholar
• Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Drug Discov. 2005; 4:206–220.
   PubMed Web of Science ®Google Scholar
• Abel U, Koch C, Speitling M, Hansske FG. Modern methods to produce natural-product libraries. Curr Opin Chem Biol. 2002; 6:453–458.
   PubMed Web of Science ®Google Scholar
• Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr. 2002; 114:433–437.
   PubMed Web of Science ®Google Scholar
• Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. J Med Chem. 2008; 51:3661–3680.
   PubMed Web of Science ®Google Scholar
• Lajiness MS, Maggiora GM, Shanmugasundaram V. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. J Med Chem. 2004; 47:4891–4896.
   PubMed Web of Science ®Google Scholar
• Rishton GM. Non-leadlikeness and leadlikeness in biochemical screening. Drug Discov Today. 2002; 8:86–96.
   Web of Science ®Google Scholar
• Hopkins AL, Groom CR, Alex A. Ligand efficiency: A useful metric for lead selection. Drug Discov Today. 2004; 9:430–431.
   PubMed Web of Science ®Google Scholar
• Bembenek SD, Tounge BA, Reynolds CH. Ligand efficiency and fragment-based drug discovery. Drug Discov Today. 2009; 14:278–283.
   PubMed Web of Science ®Google Scholar
• Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev Drug Discov. 2004; 3:660–672.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997; 23:3–25.
   Web of Science ®Google Scholar
• Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem. 2005; 48:6970–6979.
   PubMed Web of Science ®Google Scholar
• Blake JF. Chemoinformatics–Predicting the physicochemical properties of ‘drug-like’ molecules. Curr Opin Biotechnol. 2000; 11:104–107.
   PubMed Web of Science ®Google Scholar
• Livingstone DJ, van de Waterbeemd H. In silico prediction of human bioavailability. Meth Prin Med Chem. 2009; 40:433–451.
   Google Scholar
• van de Waterbeemd H. Physicochemical properties in drug profiling. Meth Prin Med Chem. 2008; 37:25–52.
   Google Scholar
• Tyrchan C, Blomberg N, Engkvist O, Kogej T, Muresan S. Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds. Bioorg Med Chem Lett. 2009; 19:6943–6947.
   PubMed Web of Science ®Google Scholar
• Wunberg T, Hendrix M, Hillisch A, Lobell M, Meier H, Schmeck C, Wild H, Hinzen B. Improving the hit-to-lead process: Data-driven assessment of drug-like and lead-like screening hits. Drug Discov Today. 2006; 11:175–180.
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302:875–878.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26:127–132.
   PubMed Web of Science ®Google Scholar
• Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008; 10:R14.
   PubMed Web of Science ®Google Scholar
• Boy MG, Wang C, Wilkinson BE, Chow VF-S, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, Chan G. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009; 129:2299–2302.
   PubMed Web of Science ®Google Scholar
• Quaedackers ME, Mol W, Korevaar SS, van Gurp EAFJ, van IJcken WFJ, Chan G, Weimar W, Baan CC. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation. 2009; 88:1002–1009.
   PubMed Web of Science ®Google Scholar
• Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, Li M, Galya L, Metcalf B, Yue T-Y, Liu P, Zhou J. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett. 2009; 11:1999–2002.
   PubMed Web of Science ®Google Scholar
• Stoll JG, Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov. 2009; 8:693–694.
   PubMed Web of Science ®Google Scholar
• Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007; 124:244–257.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006; 319:998–1008.
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009; 113:3154–3160.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008; 58:3309–3318.
   PubMed Web of Science ®Google Scholar
• Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S', Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008; 58:1433–1444.
   PubMed Web of Science ®Google Scholar
• Dambach DM. Potential adverse effects associated with inhibition of p38 α/β MAP kinases. Curr Top Med Chem. 2005; 5 10: 929–939.
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Gabriel T. Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem. 2005; 5 10: 1017–1029.
   PubMed Web of Science ®Google Scholar
• Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Invest Drugs. 2009; 12:1893–1905.
   Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov. 2005; 4:510–518.
   PubMed Web of Science ®Google Scholar
• Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest. 2008; 118 3: 825–826.
   PubMed Web of Science ®Google Scholar
• Davenport RJ, Munday JR. Alpha4-integrin antagonism–An effective approach for the treatment of inflammatory diseases?. Drug Discov Today. 2007; 12 13/14: 569–576.
   PubMed Web of Science ®Google Scholar
• Trial watch: Phase III promise for oral multiple sclerosis therapy Nat Rev Drug Discov 2009;8:98–99..
   Google Scholar
• Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. Fungal metabolites. Part II. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot. 1994; 47:208–215.
   PubMed Web of Science ®Google Scholar
• Kluepfel D, Bagli J, Baker H, Charest MP, Kudelski A. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J Antibiot. 1972; 25:109–115.
   PubMed Web of Science ®Google Scholar
• Bagii JF, Kluepfel D, StJacques M. Elucidation of structure and stereochemistry of myriocin. Novel antifungal antibiotic. J Org Chem. 1973; 38:1253–1260.
   PubMed Web of Science ®Google Scholar
• Aragozzini F, Manachini PL, Craveri R, Rindone B, Scolastico C. Isolation and structure determination of a new antifungal α-(hydroxymethyl)-α-amino acid. Tetrahedron. 1972; 28:5493–5498.
   Web of Science ®Google Scholar
• Fujita T, Yoneta M, Hirose R, Sasaki S, Inoue K, Kiuchi M, Hirase S, Adachi K, Arita M, Chiba K. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity. Bioorg Med Chem Lett. 1995; 5:847–852.
   Web of Science ®Google Scholar
• Adachi K, Kohara T, Nakao N, Arita M, Chiba K, Mishina T, Sasaki S, Fujita T. Design, synthesis, and structure–activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett. 1995; 5:853–856.
   Web of Science ®Google Scholar
• Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine-1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem. 2007; 1:11–23.
   PubMedGoogle Scholar
• Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-I/myriocin. Biochem Biophys Res Commun. 1995; 211:396–403.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296:346–349.
   PubMed Web of Science ®Google Scholar
• Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei G-J, Singer Tian MII, West S, White V, Xie J, Proia RL, Mandala S. Immune cell regulation and cardiovascular effects of sphingosine-1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004; 309:758–768.
   PubMed Web of Science ®Google Scholar
• Hale JJ, Lynch CL, Neway W, Mills SG, Hajdu RK, Carol A, Rosenbach MJ, Milligan JA, Shei GJ, Parent SA, Chrebet G, Bergstrom J, Card D, Ferrer M, Hodder P, Strulovici B, Rosen H, Mandala S. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate receptor agonists. J Med Chem. 2004; 47:6662–6665.
   PubMed Web of Science ®Google Scholar
• Evindar G, Satz AL, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Taghizadeh N, Halley K, Hutchings A, Kelley MS, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF. Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2009; 19:2315–2319.
   PubMed Web of Science ®Google Scholar
• Zhu R, Snyder AH, Kharel Y, Schaffter L, Sun Q, Kennedy PC, Lynch KR, Macdonald TL. Asymmetric synthesis of conformationally constrained Fingolimod analogues–Discovery of an orally active sphingosine-1-phosphate receptor type-1 agonist and receptor type-3 antagonist. J Med Chem. 2007; 50:6428–6435.
   PubMed Web of Science ®Google Scholar
• Zécri FJ, Albert R, Landruma G, Hinterding K, Cooke NG, Guerini D, Streiff M, Bruns C, Nuesslein-Hildesheim B. Pyrazole derived from (+)-3-carene; a novel potent, selective scaffold for sphingosine-1-phosphate (S1P1) receptor agonists. Bioorg Med Chem Lett. 2010; 20:35–37.
   PubMed Web of Science ®Google Scholar